Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
3.27
USD
|
+0.31%
|
|
+23.63%
|
-34.21%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
14
|
47.64
|
230.3
|
376.3
|
154.6
|
119.9
|
-
|
-
|
Enterprise Value (EV)
1 |
14
|
47.64
|
230.3
|
376.3
|
154.6
|
119.9
|
119.9
|
119.9
|
P/E ratio
|
-
|
-2.4
x
|
-12.3
x
|
-9.23
x
|
-3.58
x
|
-2.2
x
|
-2.03
x
|
-2.82
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
436
x
|
4.82
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
436
x
|
4.82
x
|
EV / EBITDA
|
-0.67
x
|
-3.2
x
|
-10.7
x
|
-9.03
x
|
-3.6
x
|
-2.35
x
|
-1.94
x
|
-2.22
x
|
EV / FCF
|
-0.77
x
|
-
|
-
|
-14.6
x
|
-4.6
x
|
-2.14
x
|
-1.98
x
|
-2.52
x
|
FCF Yield
|
-129%
|
-
|
-
|
-6.83%
|
-21.8%
|
-46.7%
|
-50.5%
|
-39.7%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
5,281
|
22,262
|
28,438
|
28,509
|
31,108
|
36,679
|
-
|
-
|
Reference price
2 |
2.650
|
2.140
|
8.100
|
13.20
|
4.970
|
3.270
|
3.270
|
3.270
|
Announcement Date
|
3/27/20
|
3/18/21
|
3/31/22
|
3/28/23
|
3/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
0.275
|
24.87
|
EBITDA
1 |
-20.94
|
-14.89
|
-21.43
|
-41.67
|
-42.99
|
-51
|
-61.8
|
-54
|
EBIT
1 |
-21.03
|
-14.9
|
-21.44
|
-41.67
|
-43.05
|
-51.18
|
-56.05
|
-54
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-20,382.2%
|
-217.17%
|
Earnings before Tax (EBT)
1 |
-
|
-14.85
|
-21.43
|
-42.05
|
-44.35
|
-49.4
|
-64.58
|
-33.55
|
Net income
1 |
-
|
-14.85
|
-16.92
|
-40.85
|
-42.94
|
-51.04
|
-63.73
|
-50.99
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-23,173.71%
|
-205.07%
|
EPS
2 |
-
|
-0.8900
|
-0.6600
|
-1.430
|
-1.390
|
-1.485
|
-1.614
|
-1.160
|
Free Cash Flow
1 |
-18.07
|
-
|
-
|
-25.71
|
-33.64
|
-55.96
|
-60.59
|
-47.64
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-22,034%
|
-191.58%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/27/20
|
3/18/21
|
3/31/22
|
3/28/23
|
3/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-6.561
|
-6.321
|
-8.479
|
-7.093
|
-7.279
|
-18.82
|
-9.419
|
-12.69
|
-10.51
|
-10.39
|
-11.1
|
-12.5
|
-13.3
|
-14.1
|
EBIT
1 |
-6.562
|
-6.322
|
-8.479
|
-7.093
|
-7.279
|
-18.82
|
-9.422
|
-12.7
|
-10.52
|
-10.41
|
-11.45
|
-11.77
|
-12.57
|
-13.09
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-6.961
|
-6.32
|
-8.474
|
-7.018
|
-7.424
|
-19.14
|
-9.66
|
-12.94
|
-10.85
|
-10.9
|
-11.64
|
-11.98
|
-12.68
|
-13.11
|
Net income
1 |
-6.961
|
-6.32
|
-8.474
|
-5.819
|
-7.424
|
-19.14
|
-9.66
|
-11.53
|
-10.85
|
-10.9
|
-11.77
|
-12.02
|
-13.15
|
-14.1
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.2400
|
-0.2300
|
-0.3200
|
-0.2000
|
-0.2600
|
-0.6700
|
-0.3200
|
-0.3700
|
-0.3500
|
-0.3500
|
-0.3667
|
-0.3633
|
-0.3750
|
-0.3783
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/10/21
|
3/31/22
|
5/11/22
|
8/8/22
|
11/14/22
|
3/28/23
|
5/15/23
|
8/14/23
|
11/14/23
|
3/27/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-18.1
|
-
|
-
|
-25.7
|
-33.6
|
-56
|
-60.6
|
-47.6
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
-
|
-
|
-
|
-
|
0.5
|
0.25
|
0.28
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
90.91%
|
1.14%
|
Announcement Date
|
3/27/20
|
3/18/21
|
3/31/22
|
3/28/23
|
3/27/24
|
-
|
-
|
-
|
Last Close Price
3.27
USD Average target price
14.4
USD Spread / Average Target +340.37% Consensus |
1st Jan change
|
Capi.
|
---|
| -34.21% | 120M | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.73B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|